| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| WB Predicted band size | 11 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human FXYD6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于FXYD6抗体的3篇示例参考文献(内容为虚构示例，仅用于演示格式)：
1. **文献名称**: "FXYD6蛋白在中枢神经系统中的分布及功能研究"
**作者**: Smith A, et al.
**摘要**: 通过免疫组化及Western blot技术，利用特异性FXYD6抗体揭示了该蛋白在小鼠海马体和皮质神经元中的高表达，提示其可能参与调节神经元钠钾泵活性及突触可塑性。
2. **文献名称**: "FXYD6在乳腺癌中的表达及其临床意义"
**作者**: Jones B, et al.
**摘要**: 研究采用FXYD6抗体对乳腺癌组织样本进行检测，发现FXYD6表达水平与肿瘤侵袭性呈负相关，提示其可能作为潜在预后标志物及治疗靶点。
3. **文献名称**: "FXYD6抗体在精神分裂症患者脑组织中的验证与应用"
**作者**: Chen C, et al.
**摘要**: 通过比较多种FXYD6抗体的特异性，筛选出高灵敏度的抗体用于尸检脑组织分析，发现精神分裂症患者前额叶皮层FXYD6表达显著降低，可能与离子稳态失调相关。
4. **文献名称**: "FXYD6与肾脏离子通道调控机制研究"
**作者**: Tanaka K, et al.
**摘要**: 利用基因敲除模型和FXYD6特异性抗体，证实该蛋白通过调节肾小管上皮细胞的Na+/K+-ATP酶活性影响电解质平衡，为相关代谢疾病提供新见解。
---
注：以上内容为模拟示例，实际文献需通过学术数据库(如PubMed、Web of Science)检索。
FXYD6 antibody is a research tool designed to target the FXYD6 protein, a member of the FXYD family of small membrane proteins that regulate ion transport by modulating the activity of Na+/K+-ATPase. FXYD6. also known as phosphohippolin, is primarily expressed in the brain, kidneys, and testes, where it plays a role in maintaining ion homeostasis and cellular excitability. Its interaction with Na+/K+-ATPase suggests involvement in neurological functions, including synaptic plasticity and signal transduction.
FXYD6 antibodies are typically developed as polyclonal or monoclonal reagents for applications such as Western blotting, immunohistochemistry, and immunofluorescence. These antibodies aid in studying FXYD6's expression patterns, localization, and physiological roles. Research has linked FXYD6 dysregulation to neurological disorders, such as epilepsy and cognitive impairments, as well as certain cancers, where altered ion transport may influence tumor progression.
Recent studies also explore FXYD6's potential as a biomarker or therapeutic target. However, its precise mechanisms remain partially unclear, necessitating further investigation. Validation of FXYD6 antibodies includes specificity checks via knockout controls or siRNA silencing to ensure reliable detection. As interest in ion channel-related pathologies grows, FXYD6 antibodies continue to support advances in understanding cellular physiology and disease mechanisms.
×
